SCHEMBL276174

SCHEMBL276174

O=Cc1cc(Cl)ccc1Oc1ccc(C(F)(F)F)cc1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EPAS1 Q99814 2/20 0.46
SLC6A4 P31645 2/20 0.45
HTR2A P28223 1/20 0.45
KCNH2 Q12809 1/20 0.45
FFAR1 O14842 2/20 0.42
L3MBTL1 Q9Y468 3/20 0.41
RAB9A P51151 1/20 0.41
SCN8A Q9UQD0 1/20 0.41
SCN10A Q9Y5Y9 1/20 0.41
KMT2A Q03164 2/20 0.41
MAPT P10636 2/20 0.41
KDM4E B2RXH2 1/20 0.41
MEN1 O00255 1/20 0.41
ALDH1A1 P00352 1/20 0.41
CYP1A2 P05177 1/20 0.41
CYP2D6 P10635 1/20 0.41
CYP2C9 P11712 1/20 0.41
HPGD P15428 1/20 0.41
CYP2C19 P33261 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19563652 0.91 HTR2A (0.51) EPAS1SLC6A4HTR2AKCNH2FFAR1
SCHEMBL19563733 0.83 EPAS1 (0.49) EPAS1SLC6A4HTR2AKCNH2L3MBTL1
SCHEMBL12437417 0.82 L3MBTL1 (0.41) EPAS1SLC6A4HTR2AKCNH2FFAR1
SCHEMBL276096 0.82 SLC6A4 (0.56) EPAS1SLC6A4HTR2AKCNH2FFAR1
SCHEMBL18570579 0.81 L3MBTL1 (0.46) EPAS1SLC6A4HTR2AKCNH2FFAR1
SCHEMBL12437522 0.80 PDE7A (0.56) EPAS1KMT2AMAPTKDM4EMEN1
SCHEMBL13815379 0.80 CYP1A2 (0.44) EPAS1SLC6A4HTR2AKCNH2FFAR1
SCHEMBL2419953 0.80 ALDH1A1 (0.61) SLC6A4HTR2AKCNH2KMT2AMAPT
SCHEMBL5837555 0.80 HTR2A (0.56) EPAS1SLC6A4HTR2AKCNH2FFAR1
SCHEMBL22809753 0.80 SCN8A (0.47) EPAS1SLC6A4KCNH2L3MBTL1SCN8A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8134001-B2 Spiroindolinone derivatives HOFFMANN-LA ROCHE INC. (US) 2012-03-13 US disclosed
US-8134001-B2 Spiroindolinone derivatives HOFFMANN-LA ROCHE INC. (US) 2012-03-13 US disclosed
US-8134001-B2 Spiroindolinone derivatives HOFFMANN-LA ROCHE INC. (US) 2012-03-13 US disclosed
EP-2229396-B1 SPIROINDOLINONE DERIVATIVES HOFFMANN LA ROCHE (CH) 2011-08-10 EP disclosed
EP-2229396-A1 SPIROINDOLINONE DERIVATIVES F. Hoffmann-La Roche AG (CH) 2010-09-22 EP disclosed
WO-2009077357-A1 SPIROINDOLINONE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2009-06-25 WO disclosed
WO-2009077357-A1 SPIROINDOLINONE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2009-06-25 WO disclosed
US-20090156610-A1 Spiroindolinone Derivatives DING QINGJIE 2009-06-18 US disclosed
US-20090156610-A1 Spiroindolinone Derivatives DING QINGJIE 2009-06-18 US disclosed
US-20090156610-A1 Spiroindolinone Derivatives DING QINGJIE 2009-06-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090156610-A1 Spiroindolinone Derivatives SDHA, AR, XPOT EPAS1 2981/4885SLC6A4 2563/4885HTR2A 1788/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.